Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Neoplasms, Second Primary × dostarlimab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Endometrial Neoplasms 7 Ovarian Neoplasms 6 Neoplasms 6 Uterine Cervical Neoplasms 5 Squamous Cell Carcinoma of Head and Neck 3 Rectal Neoplasms 3 Pancreatic Neoplasms 3 Neoplasm Metastasis 3 Head and Neck Neoplasms 3 Colonic Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Breast Neoplasms 3 Triple Negative Breast Neoplasms 2 Lung Neoplasms 2 Fallopian Tube Neoplasms 2 Carcinoma, Neuroendocrine 2 Vulvar Neoplasms 1 Vaginal Neoplasms 1 Turcot syndrome 1 Small Cell Lung Carcinoma 1 Sarcoma, Clear Cell 1 Sarcoma 1 Recurrence 1 Penile Neoplasms 1 Pathologic Complete Response 1 Neoplasms, Second Primary 1 Multiple Myeloma 1 Mesothelioma, Malignant 1 Mesothelioma 1 Melanoma 1

Interventions

Leucovorin 2 Irinotecan 2 Fluorouracil 2 dostarlimab 1 avelumab 1 Varenicline 1 Tobacco Use Cessation Devices 1 Temozolomide 1 Radiotherapy 1 Panitumumab 1 Nicotine Chewing Gum 1 Cetuximab 1 Bupropion 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05855811 2024-07-15

PREDOSTAR

Centre Leon Berard

Phase 2 Recruiting

Neoplasms, Recurrence, Neoplasms, Second Primary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡